



FIG. 3



(-) Betaxolol



(+) Betaxolol




FIG. 6B






FIG.7A



REPLACEMENT SHEET

FIG. 7B



REPLACEMENT SHEET

FIG. 7C





FIG. 8A



# REPLACEMENT SHEET





FIG. 9


FIG. 10C






# REPLACEMENT SHEET

FIG. 11



# REPLACEMENT SHEET

FIG. 12



# REPLACEMENT SHEET

FIG. 13







FIG. 14

CAM $\beta_2$ AR	Renilla Luciferase
------------------	--------------------

(-) Antagonist




(+) Antagonist




Upregulation monitored by increased  
luciferase activity in cells

# REPLACEMENT SHEET

FIG. 15



Paramete	Value	SE	Lower CL	Upper CL	Paramete	Value	SE	Lower CL	Upper CL
a (Iso ave)	107.98	4.99006	96.4729	119.4871	a (ave bet)	91.99781	4.066952	82.6194	101.3762
c (Iso ave)	3.04E-06	8.74E-07	1.57E-06	5.9E-06	c (ave bet)	1.16E-07	2.64E-08	6.85E-08	1.96E-07
d (Iso ave)	263.6671	9.532958	241.684	285.6501	d (ave bet)	194.6117	3.153874	187.3389	201.8846
b (Iso ave)	1	0	1	1	b (ave bet)	1	0	1	1



Paramete	Value	SE	Lower CL	Upper CL
a (ave sot)	91.61328	3.703476	83.07304	100.1535
c (ave sot)	1.59E-06	4.07E-07	8.77E-07	2.87E-06
d (ave sot)	208.4677	5.759934	195.1852	221.7501
b (ave sot)	1	0	1	1

# REPLACEMENT SHEET

FIG. 17

